Welcome to our dedicated page for Chemed SEC filings (Ticker: CHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Chemed Corp can feel like tackling two companies at once: hospice care economics in VITAS and emergency plumbing metrics in Roto-Rooter. That split shows up in every 10-K footnote, Form 4 footnote, and 8-K headline, making Chemed’s SEC filings unusually dense.
Stock Titan’s AI-powered analysis turns that complexity into clarity. Whether you need the latest Chemed quarterly earnings report 10-Q filing or want Chemed Form 4 insider transactions real-time, our platform surfaces the numbers and narrative in plain language. Instantly pinpoint hospice reimbursement rate disclosures, segment operating margins, and technician labor costs—without wading through hundreds of pages.
All Chemed filings arrive minutes after EDGAR posts. Click into:
- 10-K annual report—AI highlights VITAS patient census trends and Roto-Rooter service revenue (Chemed annual report 10-K simplified).
- 10-Q quarterly update—Compare sequential hospice margins with a one-click Chemed earnings report filing analysis.
- 8-K material events—Get alerts when Medicare rules change (Chemed 8-K material events explained).
- Form 4—Monitor executive stock moves, including CEO transactions (Chemed insider trading Form 4 transactions, Chemed executive stock transactions Form 4).
- Proxy statement (DEF 14A)—Understand how compensation aligns with both segments (Chemed proxy statement executive compensation).
Need context fast? Our summaries answer common questions like “understanding Chemed SEC documents with AI” or “where can I find Chemed’s hospice segment revenue?”. Save hours, stay informed, and make confident decisions with filings explained simply.
Chemed Corporation (CHE) Form 144 disclosure: A notice was filed reporting a proposed sale of 150 shares of the issuer's capital stock through J.P. Morgan Securities LLC on the NYSE, with an approximate sale date of 09/09/2025 and an aggregate market value of 69,567. The shares were acquired on 05/29/2025 as executive compensation from the issuer; the filing shows 277 shares were originally acquired on that date and payment was made on 05/29/2025. The filer reports 14,571,695 shares outstanding for the class. No securities were reported sold by the person in the past three months in this filing.
Joel L. Wherley, listed as an officer (CEO - Vitas Healthcare) of Chemed Corporation (CHE), filed an Initial Form 3 reporting beneficial ownership on 08/27/2025. He directly owns 659 shares of Chemed capital stock and holds stock options exercisable in 2028 and 2029 covering 6,961 and 8,382 shares at exercise prices of $509.46 and $597.70. He also holds multiple performance stock units that convert to shares if performance targets are met over 2023–2027 performance periods.
Chemed Corporation (CHE) notice of proposed sale reports an intended sale of 556 common shares with an aggregate market value of $232,410.94, representing holdings out of 14,571,695 shares outstanding. The approximate date of sale is 07/31/2025 and the transaction lists Merrill Lynch, 401 E Las Olas Blvd., Fort Lauderdale, FL as the broker and the NYSE as the exchange. The shares were acquired as stock awards: 262 shares on 05/16/2022 and 294 shares on 05/15/2023, with payment recorded on the acquisition dates. The filer indicates no securities sold in the past three months and includes the standard representation that they are unaware of undisclosed material adverse information about the issuer.
Chemed Corp. (CHE) Form 4 filing: Director George J. Walsh III purchased 200 shares of Chemed common stock on 08/04/2025 at $417.10 per share, an outlay of roughly $83,420. His direct holdings rise to 3,523 shares; he also reports 434 shares held indirectly by his spouse. No shares were sold and no derivative positions were opened or closed. The transaction modestly increases the director’s exposure—about a 6% lift in his direct stake—while leaving total company share count essentially unaffected. Insider buying by a non-executive director is often interpreted as a vote of confidence, though the amount is immaterial compared to Chemed’s ~15 million shares outstanding.
FAQ
What is the current stock price of Chemed (CHE)?
What is the market cap of Chemed (CHE)?
